On September 29, Moderna, Inc. rose 4.42% in regular trading, trading at $205.50 USD/share, with turnover of $333 million. The stock extended its rally above the $200 level, building on recent momentum that has seen shares surge approximately 29% over the past week alone.

The continued strength is driven by heightened anticipation surrounding the company's personalized mRNA cancer vaccine, intismeran autogene. Moderna recently announced that three research abstracts related to the vaccine have been accepted for presentation at the European Society for Medical Oncology annual meeting, with the most closely watched Phase 3 INTerpath-001 melanoma data set to be presented on October 24 in the highest-profile Presidential Symposium slot. Two additional abstracts will disclose clinical data on pancreatic cancer and early-stage non-small cell lung cancer applications.

Institutional sentiment has been notably bullish, with options market activity in recent sessions featuring large-scale call spread positions, including a $3.22 million bull call spread targeting the $190-$270 range through March and a $9.18 million deep in-the-money call purchase. Multiple analyst upgrades have followed the Phase 3 success reported in August, with Argus Research initiating a buy rating and a $180 target, while Barclays raised its target from $48 to $125.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)